Corporate insiders at Clearside BioMedical, Inc. (:CLSD) have decreased their position in the stock by -25.54% over the past 6 months. Insiders now own 2.20% of total outstanding shares.
Clearside BioMedical, Inc. (:CLSD) stands -10.88% away from its 50-day simple moving average and also -12.43% away from the 200-day average. Recently, the equity stands -72.10% away from the 52-week high and 26.84% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 39.11.
The consensus analysts recommendation at this point stands at 1.70 for Clearside BioMedical, Inc.. This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. Further, analysts have a 12 month target price of $20.25 on company shares. This is according to the analysts polled by Thomson Reuters which have recently published research reports on the firm.